Aptinyx (NASDAQ: APTX)
Some price data may be temporarily unavailable.
Aptinyx Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aptinyx Company Info
Aptinyx Inc. is a clinical stage biopharmaceutical company, which engages in discovery, development, and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
News & Analysis
3 Top Healthcare Stocks Under $5
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
Why Aptinyx Stock Sank Today
Investors reacted negatively to the company's announcement of a secondary stock offering.
Why Aptinyx Stock Is Soaring Today
The biotech's PTSD drug hit the mark in a midstage trial.
Why Aptinyx Stock Is Soaring Today
Shares rose in response to news that a large investment management company has purchased a significant ownership position.
Why Ford Motor, Snap, and Aptinyx Slumped Today
Despite a good day for markets, these stocks missed out.
Here's Why Aptinyx Got Crushed Today
The company reported results for an important phase 2 trial.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.